Cancer Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Breast Cancer

Epirubicin, vinorelbine, and cisplatin are effective in advanced breast cancer

"Our objective was to evaluate the activity and safety of the combination of cisplatin, epirubicin and vinorelbine (CEV) in advanced breast cancer patients. Patients with advanced breast cancer, locally advanced or metastatic, received epirubicin 75 mg/m² and cisplatin 50 mg/m² on day 1, and vinorelbine 25 mg/m² on day 5. Cycles were repeated every 3 weeks," investigators in Italy report.

"A total of 35 patients were treated. Thirty-one patients were evaluated for response. One hundred...

• View Other Issues of Cancer Weekly
  
• View Other NewsRx Publications